🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Compound trial record
Trackers Drugs Trial finder
Compound · clinical trials

Peginterferon α-2b

Source: ClinicalTrials.gov, U.S. National Library of Medicine — the 6 trials in our China register that name Peginterferon α-2b as an intervention. Synced 24 Sep 2026
6Trials tracked
4Recruiting now
5Lead sponsors
1Country register
Maintained by Sreepriya Prasannan
MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist
Compiled from ClinicalTrials.gov registry records · Last verified · Editorial standards

Peginterferon α-2b is named as a drug or biological intervention in 6 clinical trials in our China trial register, 4 of which are recruiting. Lead sponsors include Xiamen Amoytop Biotech Co., Ltd. (2), The First Affiliated Hospital of Zhengzhou University (1) and Zhenya Hong (1). Registered phases: Not applicable, Observational and Phase 2. Conditions studied include Essential Thrombocythemia; Chronic Hepatitis B; Chronic Hepatitis b.

01

Clinical trials of Peginterferon α-2b

6 trials
NCT IDStudyPhaseStatusLead sponsorRegister
NCT06552429 Peginterferon α-2b Injection for Hydroxyurea Resistant or Intolerant ET (ClinicalTrials.gov ↗)
Essential Thrombocythemia
Phase 2 Recruiting Xiamen Amoytop Biotech Co., Ltd. China
NCT07169656 Observation Study on Reducing the Risk of Liver Cancer Associated With Hepatitis B (Zhiyuan) Project. (ClinicalTrials.gov ↗)
Chronic Hepatitis b
Observational Recruiting The First Affiliated Hospital of Zhengzhou University China
NCT06734637 Efficacy and Safety of Peginterferon in ET and PV. (ClinicalTrials.gov ↗)
Essential Thrombocythemia, Polycythemia Vera
Not applicable Recruiting Zhenya Hong China
NCT06881056 Peginterferon α-2b Injection for Aerosol Therapy in Pediatric Respiratory Syncytial Virus Pneumonia (ClinicalTrials.gov ↗)
Respiratory Syncytial Virus (RSV)
Not applicable Recruiting West China Second University Hospital China
NCT07438093 Safety, Tolerability, and Preliminary Efficacy of Peginterferon α-2b in Combination With an Anti-PD-1 Antibody in Patients With Advanced or Metastatic Malignant Solid Tumors (ClinicalTrials.gov ↗)
Advanced Solid Tumors
Not applicable Not yet open The First Affiliated Hospital of Xiamen University China
NCT06707922 A Follow-up Study of Peginterferon Alfa-2b Combined With TDF in Patients With Chronic Hepatitis B (ClinicalTrials.gov ↗)
Chronic Hepatitis B
Not applicable By invitation Xiamen Amoytop Biotech Co., Ltd. China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.

02

Conditions studied

6 conditions
Condition (as registered)Trials
Essential Thrombocythemia2
Chronic Hepatitis B1
Chronic Hepatitis b1
Polycythemia Vera1
Advanced Solid Tumors1
Respiratory Syncytial Virus (RSV)1
03

Sponsors

lead sponsor per trial
Lead sponsorTrials
Xiamen Amoytop Biotech Co., Ltd.2
The First Affiliated Hospital of Zhengzhou University1
Zhenya Hong1
The First Affiliated Hospital of Xiamen University1
West China Second University Hospital1
04

Trials by country register

RegisterPeginterferon α-2b trials
Clinical trials in China6

A trial with sites in more than one country appears in each of those registers.

How this page is built

Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Peginterferon α-2b works or whether it is effective. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Peginterferon α-2b (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 24 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.